Refine by
Inflammatory Drug Articles & Analysis
19 news found
These mouse models of influenza A virus can also be used to evaluate different classes of therapeutic agents such as antivirals, anti-inflammatory drugs and pulmonary therapeutics, and to study viral pathogenesis and humoral responses in mice infected with influenza A virus. ...
These APIs will serve as essential components in the formulation of various drugs. APIs are the primary components of pharmaceutical products that exert pharmacological activity. CD Formulation's extensive range of APIs can be classified into amino acid series, antibacterial, anti-inflammatory and antiviral series, cardiovascular series, hormone series and other ...
Lenalidomide, as an oral immunomodulatory drug, revealed a good safety profile. Parecoxib Sodium Alfa Chemistry offers high-quality parecoxib sodium as API to support the amide prodrug of the cyclooxygenase II (COX-2)-selective inhibitor, non-steroidal anti-inflammatory drug (NSAID) valdecoxib, which has anti-inflammatory, ...
(“BRIM,” TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate for Dry Eye Disease (DED), BRM421, at the End of Phase 2 Meeting. ...
Prostatitis is a disease characterized by the presence of inflammation and/or infection localized in the prostate gland. ...
("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. ...
Patients at Higher Risk of Wound Infections Some urgent care patients may have underlying conditions that could increase their risk of wound infections either due to the condition itself or the drugs used to treat it. Some examples include: Patients with diabetes. ...
Healx has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for the Phase 2a clinical study of the compound HLX-0201 for Fragile X syndrome. The clinical study will attempt to find at least one novel and effective combination therapy for Fragile X syndrome - the world’s leading inherited cause of autism and learning difficulties which affects ...
Lyra’s XTreo™ platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex. The company’s current pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy for months following a single non-invasive, ...
Lyra’s XTreo™ platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex. The company’s current pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy for months following a single non-invasive, ...
Bilix is a biotech company that develops bilirubin-based anti-inflammatory drugs, anti-cancer drug delivery systems (DDS), and contrast agents. ...
Drug discovery is often a laborious, and time-consuming task. Now, Creative Biolabs has optimized a portfolio of antiviral drug discovery services, especially neutralizing antibody development for SARS-CoV-2. ...
(NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab. ...
” succeeded in chemical synthesis of bilirubin for the first time in the world The nanoparticle itself: BRIXELLE-INFLA anti-inflammatory drug Nanoparticles + Hydrophobic Drugs: BRIXELLE-ONCO Anticancer Drug Delivery System Nanoparticles + SPION: BRIXELLE-SHINE Cancer Tumor Contrast Agent To see video, please click ...
The currently accepted procedure is, to use drug delivery devices to deliver drugs that inhibit the inflammatory and proliferative pathways that lead to restenosis. Sirolimus is widely accepted as a drug of choice for such a purpose. Several studies have demonstrated that Erectile Dysfunction (ED) is increasingly prevalent with ...
tiakis BIOTECH AG today announced the start of the clinical development for the subcutaneous use of tiakis lead investigational drug candidate Elafin (INN: Tiprelestat). The Duke University Early Phase Research Unit initiated the recruitment of healthy individuals for the Phase I clinical trial in the U.S. to assess the safety and tolerability of repeated single doses of Elafin. ...
About tiakis Elafin clinical development program tiakis biopharmaceutical drug candidate Elafin promises an excellent therapeutic benefit risk profile for the use as an anti-inflammatory and tissue protective drug. ...
(“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the use of the Company’s ...
Changes in complex microbial communities known as ‘biofilms’ at the bottom of rivers can reveal the effects of pesticide and pharmaceutical pollution of river water, according to a recent study. Painkillers and anti-inflammatory drugs were found to have a significant effect on the structure and functioning of the biofilms. ...